Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 957878, 11 pages
http://dx.doi.org/10.1155/2013/957878
Review Article

The Multifaceted Role of Th17 Lymphocytes and Their Associated Cytokines in Cancer

1Cancer Biology Graduate Interdisciplinary Program and Department of Pediatrics, Steele Children’s Research Center, University of Arizona, 1501 N. Campbell Avenue, P.O. Box 245073, Tucson, AZ 85724-5073, USA
2Department of Immunobiology, BIO5 Institute and Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA

Received 22 March 2013; Accepted 11 December 2013

Academic Editor: William O’Connor Jr.

Copyright © 2013 Darya Alizadeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Sun and M. J. Bevan, “Defective CD8 T cell memory following acute infection without CD4 T cell help,” Science, vol. 300, no. 5617, pp. 339–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Sun, M. A. Williams, and M. J. Bevan, “CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection,” Nature Immunology, vol. 5, no. 9, pp. 927–933, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Mitsdoerffer, Y. Lee, A. Jäger et al., “Proinflammatory T helper type 17 cells are effective B-cell helpers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14292–14297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. N. Kelly, M. Zheng, S. Ruan, J. Kolls, A. D'Souza, and J. E. Shellito, “Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina,” Journal of Immunology, vol. 190, no. 1, pp. 285–295, 2013. View at Publisher · View at Google Scholar
  5. D. G. DeNardo, J. B. Barreto, P. Andreu et al., “CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages,” Cancer Cell, vol. 16, no. 2, pp. 91–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Veldhoen, H. Moncrieffe, R. J. Hocking, C. J. Atkins, and B. Stockinger, “Modulation of dendritic cell function by naive and regulatory CD4+ T cells,” Journal of Immunology, vol. 176, no. 10, pp. 6202–6210, 2006. View at Google Scholar · View at Scopus
  7. S. Romagnani, “The Th1/Th2 paradigm,” Immunology Today, vol. 18, no. 6, pp. 263–266, 1997. View at Google Scholar · View at Scopus
  8. T. R. Mosmann and R. L. Coffman, “TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties,” Annual Review of Immunology, vol. 7, pp. 145–173, 1989. View at Google Scholar · View at Scopus
  9. S. J. Szabo, S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher, “A novel transcription factor, T-bet, directs Th1 lineage commitment,” Cell, vol. 100, no. 6, pp. 655–669, 2000. View at Google Scholar · View at Scopus
  10. A. J. McAdam, B. A. Pulaski, S. S. Harkins, E. K. Hutter, E. M. Lord, and J. G. Frelinger, “Synergistic effects of co-expression of the Th1 cytokines IL-2 and IFN-γ on generation of murine tumor-reactive cytotoxic cells,” International Journal of Cancer, vol. 61, no. 5, pp. 628–634, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. K. A. Hoag, M. F. Lipscomb, A. A. Izzo, and N. E. Street, “IL-12 and IFN-γ are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 17, no. 6, pp. 733–739, 1997. View at Google Scholar · View at Scopus
  12. K. Kohno, J. Kataoka, T. Ohtsuki et al., “IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12,” Journal of Immunology, vol. 158, no. 4, pp. 1541–1550, 1997. View at Google Scholar · View at Scopus
  13. A. Sjölander, T. M. Baldwin, J. M. Curtis, and E. Handman, “Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis,” Journal of Immunology, vol. 160, no. 8, pp. 3949–3957, 1998. View at Google Scholar · View at Scopus
  14. W.-P. Zheng and R. A. Flavell, “The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells,” Cell, vol. 89, no. 4, pp. 587–596, 1997. View at Google Scholar · View at Scopus
  15. E. J. Pearce, P. Caspar, J.-M. Grzych, F. A. Lewis, and A. Sher, “Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni,” Journal of Experimental Medicine, vol. 173, no. 1, pp. 159–166, 1991. View at Publisher · View at Google Scholar · View at Scopus
  16. E. M. Shevach, R. A. DiPaolo, J. Andersson, D.-M. Zhao, G. L. Stephens, and A. M. Thornton, “The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells,” Immunological Reviews, vol. 212, pp. 60–73, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. M. Shevach, “Regulatory/suppressor T cells in health and disease,” Arthritis and Rheumatism, vol. 50, no. 9, pp. 2721–2724, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. E. M. Shevach, “Regulatory T cells. Introduction,” Seminars in Immunology, vol. 16, no. 2, pp. 69–71, 2004. View at Google Scholar
  19. S. Sakaguchi, “Regulatory T cells: history and perspective,” Methods in Molecular Biology, vol. 707, pp. 3–17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Fehérvari and S. Sakaguchi, “Development and function of CD25+CD4+ regulatory T cells,” Current Opinion in Immunology, vol. 16, no. 2, pp. 203–208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Y. Rudensky, “Regulatory T cells and Foxp3,” Immunological Reviews, vol. 241, no. 1, pp. 260–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Z. Josefowicz, L.-F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. P. Colombo and S. Piconese, “Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy,” Nature Reviews Cancer, vol. 7, no. 11, pp. 880–887, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Bluestone and A. K. Abbas, “Natural versus adaptive regulatory T cells,” Nature Reviews Immunology, vol. 3, no. 3, pp. 253–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Z. Song, J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz, “IL-2 is essential for TGF-β to convert naive CD4+CD25—cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells,” Journal of Immunology, vol. 178, no. 4, pp. 2018–2027, 2007. View at Google Scholar · View at Scopus
  28. Q. Shi, H. Cao, J. Liu et al., “CD4+Foxp3+regulatory T cells induced by TGF-β, IL-2 and all-trans retinoic acid attenuate obliterative bronchiolitis in rat trachea transplantation,” International Immunopharmacology, vol. 11, no. 11, pp. 1887–1894, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. T. S. Davidson, R. J. DiPaolo, J. Andersson, and E. M. Shevach, “Cutting edge: IL-2 is essential for TGF-β-mediated induction of Foxp3+ T regulatory cells,” Journal of Immunology, vol. 178, no. 7, pp. 4022–4026, 2007. View at Google Scholar · View at Scopus
  30. M. Galgani, A. di Giacomo, G. Matarese, and A. la Cava, “The Yin and Yang of CD4+ regulatory T cells in autoimmunity and cancer,” Current Medicinal Chemistry, vol. 16, no. 35, pp. 4626–4631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Danese and S. Rutella, “The janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity,” Current Medicinal Chemistry, vol. 14, no. 6, pp. 649–666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Muranski and N. P. Restifo, “Essentials of Th17 cell commitment and plasticity,” Blood, vol. 121, no. 13, pp. 2402–2414, 2013. View at Publisher · View at Google Scholar
  34. C. M. Wilke, K. Bishop, D. Fox, and W. Zou, “Deciphering the role of Th17 cells in human disease,” Trends in Immunology, vol. 32, no. 12, pp. 603–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. X. O. Yang, B. P. Pappu, R. Nurieva et al., “T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ,” Immunity, vol. 28, no. 1, pp. 29–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Kryczek, M. Banerjee, P. Cheng et al., “Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments,” Blood, vol. 114, no. 6, pp. 1141–1149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Kebir, I. Ifergan, J. I. Alvarez et al., “Preferential recruitment of interferon-γ-expressing TH17 cells in multiple sclerosis,” Annals of Neurology, vol. 66, no. 3, pp. 390–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Korn, E. Bettelli, W. Gao et al., “IL-21 initiates an alternative pathway to induce proinflammatory T H17 cells,” Nature, vol. 448, no. 7152, pp. 484–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Kryczek, E. Zhao, Y. Liu et al., “Human TH17 cells are long-lived effector memory cells,” Science Translational Medicine, vol. 3, no. 104, Article ID 104ra100, 2011. View at Google Scholar · View at Scopus
  41. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. K. A. Charles, H. Kulbe, R. Soper et al., “The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans,” The Journal of Clinical Investigation, vol. 119, no. 10, pp. 3011–3023, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Pelletier, L. Maggi, A. Micheletti et al., “Evidence for a cross-talk between human neutrophils and Th17 cells,” Blood, vol. 115, no. 2, pp. 335–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Ankathatti Munegowda, Y. Deng, S. J. Mulligan, and J. Xiang, “Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity,” Cancer Immunology, Immunotherapy, vol. 60, no. 10, pp. 1473–1484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Dong, “Mouse Th17 cells: current understanding of their generation and regulation,” European Journal of Immunology, vol. 39, no. 3, pp. 640–644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Korn, M. Mitsdoerffer, A. L. Croxford et al., “IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 47, pp. 18460–18465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Yang, D. E. Anderson, C. Baecher-Allan et al., “IL-21 and TGF-β are required for differentiation of human T H17 cells,” Nature, vol. 454, no. 7202, pp. 350–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Nurieva, X. O. Yang, G. Martinez et al., “Essential autocrine regulation by IL-21 in the generation of inflammatory T cells,” Nature, vol. 448, no. 7152, pp. 480–483, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Parham, M. Chirica, J. Timans et al., “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R,” Journal of Immunology, vol. 168, no. 11, pp. 5699–5708, 2002. View at Google Scholar · View at Scopus
  50. G. L. Stritesky, N. Yeh, and M. H. Kaplan, “IL-23 promotes maintenance but not commitment to the Th17 lineage,” Journal of Immunology, vol. 181, no. 9, pp. 5948–5955, 2008. View at Google Scholar · View at Scopus
  51. D. J. Cua, J. Sherlock, Y. Chen et al., “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” Nature, vol. 421, no. 6924, pp. 744–748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. C. A. Murphy, C. L. Langrish, Y. Chen et al., “Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation,” Journal of Experimental Medicine, vol. 198, no. 12, pp. 1951–1957, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Chung, S. H. Chang, G. J. Martinez et al., “Critical regulation of early Th17 cell differentiation by interleukin-1 signaling,” Immunity, vol. 30, no. 4, pp. 576–587, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Q. Chen, W. Yang, S. Gupta et al., “IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor,” Immunity, vol. 29, no. 6, pp. 899–911, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. E. V. Acosta-Rodriguez, L. Rivino, J. Geginat et al., “Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells,” Nature Immunology, vol. 8, no. 6, pp. 639–646, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. N. J. Wilson, K. Boniface, J. R. Chan et al., “Development, cytokine profile and function of human interleukin 17-producing helper T cells,” Nature Immunology, vol. 8, no. 9, pp. 950–957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Ghoreschi, A. Laurence, X.-P. Yang et al., “Generation of pathogenic TH 17 cells in the absence of TGF-β 2 signalling,” Nature, vol. 467, no. 7318, pp. 967–971, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. V. Soumelis and E. Volpe, “TH17 differentiation, a complex process in mouse and man,” Médecine Sciences, vol. 24, no. 11, pp. 925–927, 2008. View at Google Scholar · View at Scopus
  60. N. Manel, D. Unutmaz, and D. R. Littman, “The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt,” Nature Immunology, vol. 9, no. 6, pp. 641–649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Hebel, M. Rudolph, B. Kosak, H.-D. Chang, J. Butzmann, and M. C. Brunner-Weinzierl, “IL-1β and TGF-β act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4+ T cells,” Journal of Immunology, vol. 187, no. 11, pp. 5627–5635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Kryczek, S. Wei, W. Gong et al., “Cutting edge: IFN-γ enables APC to promote memory Th17 and Abate Th1 cell development,” Journal of Immunology, vol. 181, no. 9, pp. 5842–5846, 2008. View at Google Scholar · View at Scopus
  64. H. J. P. M. Koenen, R. L. Smeets, P. M. Vink, E. van Rijssen, A. M. H. Boots, and I. Joosten, “Human CD25highFoxp3pos regulatory T cells differentiate into IL-17 producing cells,” Blood, vol. 112, no. 6, pp. 2340–2352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Hori, “Developmental plasticity of Foxp3+ regulatory T cells,” Current Opinion in Immunology, vol. 22, no. 5, pp. 575–582, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. D. M. Tartar, A. M. VanMorlan, X. Wan et al., “FoxP3+RORγt+ T helper intermediates display suppressive function against autoimmune diabetes,” Journal of Immunology, vol. 184, no. 7, pp. 3377–3385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Veldhoen, R. J. Hocking, R. A. Flavell, and B. Stockinger, “Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease,” Nature Immunology, vol. 7, no. 11, pp. 1151–1156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. M. O. Li, Y. Y. Wan, and R. A. Flavell, “T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation,” Immunity, vol. 26, no. 5, pp. 579–591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Zhou, J. E. Lopes, M. M. W. Chong et al., “TGF-Β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function,” Nature, vol. 453, no. 7192, pp. 236–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. M. D. Sharma, D.-Y. Hou, B. Baban et al., “Reprogrammed Foxp3+ regulatory T cells provide essential help to support cross-presentation and CD8+ T cell priming in naive mice,” Immunity, vol. 33, no. 6, pp. 942–954, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. X. O. Yang, R. Nurieva, G. J. Martinez et al., “Molecular antagonism and plasticity of regulatory and inflammatory T cell programs,” Immunity, vol. 29, no. 1, pp. 44–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Ayyoub, C. Raffin, and D. Valmori, “Generation of Th17 from human naive CD4+ T cells preferentially occurs from FOXP3+ Tregs upon costimulation via CD28 or CD5,” Blood, vol. 119, no. 20, pp. 4810–4812, 2012. View at Google Scholar
  73. D. Valmori, C. Raffin, I. Raimbaud, and M. Ayyoub, “Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineagespecific polarizing factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 45, pp. 19402–19407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Muranski, Z. A. Borman, S. P. Kerkar et al., “Th17 cells are long lived and retain a stem cell-like molecular signature,” Immunity, vol. 35, no. 6, pp. 972–985, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Peters, Y. Lee, and V. K. Kuchroo, “The many faces of Th17 cells,” Current Opinion in Immunology, vol. 23, no. 6, pp. 702–706, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. K. Lee, H. Turner, C. L. Maynard et al., “Late developmental plasticity in the T helper 17 lineage,” Immunity, vol. 30, no. 1, pp. 92–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, “Interleukin-17 family and IL-17 receptors,” Cytokine and Growth Factor Reviews, vol. 14, no. 2, pp. 155–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Lockhart, A. M. Green, and J. L. Flynn, “IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection,” Journal of Immunology, vol. 177, no. 7, pp. 4662–4669, 2006. View at Google Scholar · View at Scopus
  79. Y. Yoshiga, D. Goto, D. Segawa et al., “Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis,” International Journal of Molecular Medicine, vol. 22, no. 3, pp. 369–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S.-J. Liu, J.-P. Tsai, C.-R. Shen et al., “Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6,” Journal of Leukocyte Biology, vol. 82, no. 2, pp. 354–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. X. Zhu, L. A. Mulcahy, R. A. A. Mohammed et al., “IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines,” Breast Cancer Research, vol. 10, no. 6, article R95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Ferretti, O. Bonneau, G. R. Dubois, C. E. Jones, and A. Trifilieff, “Il-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger,” Journal of Immunology, vol. 170, no. 4, pp. 2106–2112, 2003. View at Google Scholar · View at Scopus
  83. D.-M. Kuang, C. Peng, Q. Zhao et al., “Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients,” Journal of Immunology, vol. 185, no. 3, pp. 1544–1549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. Z. Yang, B. Zhang, D. Li et al., “Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model,” PLoS ONE, vol. 5, no. 1, Article ID e8922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. M. D. L. L. Garcia-Hernandez, H. Hamada, J. B. Reome, S. K. Misra, M. P. Tighe, and R. W. Dutton, “Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice,” Journal of Immunology, vol. 184, no. 8, pp. 4215–4227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. C. S. Hinrichs, A. Kaiser, C. M. Paulos et al., “Type 17 CD8+ T cells display enhanced antitumor immunity,” Blood, vol. 114, no. 3, pp. 596–599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Li, L. Huang, A. L. Vergis et al., “IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury,” The Journal of Clinical Investigation, vol. 120, no. 1, pp. 331–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Liu, Y. Duan, X. Cheng et al., “IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma,” Biochemical and Biophysical Research Communications, vol. 407, no. 2, pp. 348–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Numasaki, J.-I. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Ryu, J. H. Lee, and S. I. Kim, “IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes,” Clinical Rheumatology, vol. 25, no. 1, pp. 16–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. D. He, H. Li, N. Yusuf et al., “IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells,” Journal of Immunology, vol. 184, no. 5, pp. 2281–2288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Wang, T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu, “IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1457–1464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. I. Kryczek, S. Wei, W. Szeliga, L. Vatan, and W. Zou, “Endogenous IL-17 contributes to reduced tumor growth and metastasis,” Blood, vol. 114, no. 2, pp. 357–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. J.-P. Zhang, J. Yan, J. Xu et al., “Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients,” Journal of Hepatology, vol. 50, no. 5, pp. 980–989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. X. Chen, J. Wan, J. Liu et al., “Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients,” Lung Cancer, vol. 69, no. 3, pp. 348–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. X. Su, J. Ye, E. C. Hsueh, Y. Zhang, D. F. Hoft, and G. Peng, “Tumor microenvironments direct the recruitment and expansion of human Th17 cells,” Journal of Immunology, vol. 184, no. 3, pp. 1630–1641, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Tian, C. Yuan, D. Ma et al., “IL-21 and IL-12 inhibit differentiation of Treg and TH17 cells and enhance cytotoxicity of peripheral blood mononuclear cells in patients with cervical cancer,” International Journal of Gynecological Cancer, vol. 21, no. 9, pp. 1672–1678, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Søndergaard, K. S. Frederiksen, P. Thygesen et al., “Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors,” Cancer Immunology, Immunotherapy, vol. 56, no. 9, pp. 1417–1428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. S. J. Aujla, Y. R. Chan, M. Zheng et al., “IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia,” Nature Medicine, vol. 14, no. 3, pp. 275–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. Y. Zheng, D. M. Danilenko, P. Valdez et al., “Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis,” Nature, vol. 445, no. 7128, pp. 648–651, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. A. L. Gurney, “IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues,” International Immunopharmacology, vol. 4, no. 5, pp. 669–677, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto, “Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells,” Nature Immunology, vol. 10, no. 8, pp. 857–863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. R. Jiang, Z. Tan, L. Deng et al., “Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3,” Hepatology, vol. 54, no. 3, pp. 900–909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Jiang, H. Wang, L. Deng et al., “IL-22 is related to development of human colon cancer by activation of STAT3,” BMC Cancer, vol. 13, no. 1, article 59, 2013. View at Publisher · View at Google Scholar
  105. T. Liu, L. Peng, P. Yu et al., “Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer,” Journal of Clinical Immunology, vol. 32, no. 6, pp. 1332–1339, 2012. View at Publisher · View at Google Scholar
  106. S. Rutz, R. Noubade, C. Eidenschenk et al., “Transcription factor c-Maf mediates the TGF-β-dependent suppression of IL-22 production in TH17 cells,” Nature Immunology, vol. 12, no. 12, pp. 1238–1245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. V. Lazarevic, X. Chen, J.-H. Shim et al., “T-bet represses TH 17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt,” Nature Immunology, vol. 12, no. 1, pp. 96–104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Zhuang, L.-S. Peng, Y.-L. Zhao et al., “Increased intratumoral IL-22-producing CD4+ T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival,” Cancer Immunology, Immunotherapy, vol. 61, no. 11, pp. 1965–1975, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. G. F. Weber, F. C. Gaertner, W. Erl et al., “IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase,” Journal of Immunology, vol. 177, no. 11, pp. 8266–8272, 2006. View at Google Scholar · View at Scopus
  110. L. M. Curd, S. E. Favors, and R. K. Gregg, “Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells,” Clinical and Experimental Immunology, vol. 168, no. 2, pp. 192–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. Z. J. Ye, Q. Zhou, W. Yin et al., “Interleukin 22-producing CD4+ T cells in malignant pleural effusion,” Cancer Letters, vol. 326, no. 1, pp. 23–32, 2012. View at Publisher · View at Google Scholar
  112. P. Ragnhammar, “Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors,” Medical Oncology, vol. 13, no. 3, pp. 167–176, 1996. View at Google Scholar · View at Scopus
  113. P. Ragnhammar and M. Wadhwa, “Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy,” Medical Oncology, vol. 13, no. 3, pp. 161–166, 1996. View at Google Scholar · View at Scopus
  114. L. Codarri, G. Gyülvészii, V. Tosevski et al., “RORγ3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation,” Nature Immunology, vol. 12, no. 6, pp. 560–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. M. El-Behi, B. Ciric, H. Dai et al., “The encephalitogenicity of TH 17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF,” Nature Immunology, vol. 12, no. 6, pp. 568–575, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Abromson-Leeman, R. T. Bronson, and M. E. Dorf, “Encephalitogenic T cells that stably express both T-bet and RORγt consistently produce IFNγ but have a spectrum of IL-17 profiles,” Journal of Neuroimmunology, vol. 215, no. 1-2, pp. 10–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. T. Iida, M. Iwahashi, M. Katsuda et al., “Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer,” Oncology Reports, vol. 25, no. 5, pp. 1271–1277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. S. He, M. Fei, Y. Wu et al., “Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients,” International Journal of Molecular Sciences, vol. 12, no. 11, pp. 7424–7437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. K. S. Sfanos, T. C. Bruno, C. H. Maris et al., “Phenotypic analysis of prostate-infiltrating lymphocytes reveals T H17 and Treg skewing,” Clinical Cancer Research, vol. 14, no. 11, pp. 3254–3261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. E. Derhovanessian, V. Adams, K. Hähnel et al., “Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients,” International Journal of Cancer, vol. 125, no. 6, pp. 1372–1379, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. Z.-J. Ye, Q. Zhou, Y.-Y. Gu et al., “Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion,” Journal of Immunology, vol. 185, no. 10, pp. 6348–6354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. J. L. Gnerlich, J. B. Mitchem, J. S. Weir et al., “Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer,” Journal of Immunology, vol. 185, no. 7, pp. 4063–4071, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. M. D. Sharma, D.-Y. Hou, Y. Liu et al., “Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes,” Blood, vol. 113, no. 24, pp. 6102–6111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. P. Muranski, A. Boni, P. A. Antony et al., “Tumor-specific Th17-polarized cells eradicate large established melanoma,” Blood, vol. 112, no. 2, pp. 362–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. D. Alizadeh, M. Trad, N. T. Hanke et al., “Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer,” Cancer Research, 2013. View at Publisher · View at Google Scholar
  126. F. Chalmin, G. Mignot, M. Bruchard et al., “Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression,” Immunity, vol. 36, no. 3, pp. 362–373, 2012. View at Publisher · View at Google Scholar · View at Scopus